104 results
8-K/A
EX-99.2
LSTA
Lisata Therapeutics Inc
4 Oct 22
Other Events
4:42pm
could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.
If Cend fails to comply with environmental … on the success of its business.
Cend is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
424B3
LSTA
Lisata Therapeutics Inc
29 Jul 22
Prospectus supplement
4:06pm
with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material … adverse effect on the success of its business.
Cend is subject to numerous environmental, health and safety laws and regulations, including those
8-K
EX-2.1
bubgrlf5i lb76rn2
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-10.1
l02td
4 Jun 21
Entry into a Material Definitive Agreement
4:44pm
D
87fe6xim 887p
1 Feb 21
$25M in equity / options / securities to be acquired, sold $25M, 23 investors
12:53pm
8-K
EX-10.1
gqutb
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
D
kgazioxw8iqonzlew5x
27 Jul 20
$2M in options / securities to be acquired, sold $2M, 3 investors
9:28am
8-K
EX-10.1
pda2rpv
10 Jul 20
Entry into a Material Definitive Agreement
4:41pm
D
06o yetfos0d
5 Jun 20
$2.15M in options / securities to be acquired, sold $2.15M, 6 investors
12:23pm
8-K
EX-10.1
0df7yakbzxg
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
D
3wm8pym9
12 May 20
$2.43M in options / securities to be acquired, sold $2.43M, 5 investors
1:44pm
8-K
EX-10.1
o4zc9
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-10.1
qvn elknip
14 Mar 19
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
4:18pm